We recently compiled a list of the 10 Best Skincare Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Hims & Hers Health (NYSE: HIMS) has been a top healthcare stock to own over the past five years, soaring by around 350% ...

Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer healthcare platform said it couldn’t guarantee it would be able to continue ...

While Hims offers more options for sexual health and hair loss, Roman offers more options overall. Here’s our full breakdown of Hims vs. Roman for erectile dysfunction, hair loss, and more.

Shares of direct-to-consumer healthcare platform Hims & Hers (HIMS) raced 60% higher over the past week after a successful Super Bowl ad, despite lingering disappointment over its earnings report.

Hims & Hers Health (HIMS) is an intriguing stock strategically positioned in the rapidly expanding telehealth market. However, this week’s ...

Hims and Roman are telehealth companies that sell prescription and nonprescription products to treat erectile dysfunction (ED), hair loss, and premature ejaculation (PE). Both ED and hair loss can ...

Hims & Hers (HIMS) stock is sinking 20% today after Eli Lilly (LLY) unveiled significantly cheaper versions of its popular weight-loss drugs today. Additionally, the FDA last week hindered the ...

HIMS stock is going bananas with the stock up nearly 200% YTD at one point. However, the stock sold off due to the FDA's announcement that semaglutide will be taken off the shortage list. While ...

Hims & Hers Health, Inc. (NYSE:HIMS) stock is trading lower on Wednesday, with a session volume of 7.7 million compared to the average volume of 19.34 million, as per data from Benzinga Pro.

In this article, we are going to take a look at where Hims & Hers Health, Inc. (NYSE:HIMS) stands against the other skincare stocks. According to NielsenIQ, the global beauty market is expected to ...